During the Dutch Life Sciences Conference, Myriagon was announced as the winner of the Venture Challenge Fall 2025.
This initiative aims to develop a new class of analgesics for patients suffering from chemotherapy-induced neuropathy, one of the most debilitating side effects of cancer treatment.
The jury praised Myriagon for its strong scientific foundation, impressive progress within an academic environment.
Myriagon’s peripherally acting MAGL inhibitors demonstrate compelling pain reduction in preclinical models without adverse effects on the central nervous system, offering the potential for a safer solution.
Oncode Institute played an important role in the early development of this technology. The institute supported the research through translational guidance and financial support focused on IP protection and medicinal chemistry. This aligns with Oncode Institute’s broader mission to translate scientific breakthroughs into better treatments for patients while also creating economic impact.
Impact for Patients and for the Economy
Chemotherapy-induced nerve pain has profound consequences for quality of life and can limit the effectiveness of cancer treatment. By making better pain medication available, Myriagon can support patients while also helping clinicians optimize treatment regimens.
Myriagon’s success further strengthens the Dutch innovation landscape. Initiatives like these stimulate new business activity, create high-quality jobs, attract investment and contribute to sustainable economic growth in the biomedical sector.
Award Ceremony
Myriagon receives €25,000 to support. Oncode Institute looks forward to the coming phase together with partners, investors and clinicians who can help shape the future clinical studies.
Mirjam Huizenga, Founder Myriagon
'We often hear from patients how deeply nerve pain affects their daily lives. That is what drives us. This award feels like recognition that we are on the right path—and a push forward to keep building toward clinical studies. Ultimately, we are doing this to offer people living with severe pain a new and better outlook.'
Mario van der Stelt, Oncode Investigator
“Many patients live with pain that dominates their lives, while existing treatments often fall short. That is exactly why this research matters. This award shows that our efforts are not only scientifically strong, but also socially meaningful. It gives us extra motivation to keep going until this discovery can truly make a difference for patients.”